Clinical trials: NAsal MEthicillin-resistant Staphylococcus
NAsal MEthicillin-resistant Staphylococcus
Prevalence of Multi-Drug Resistant Bacteria in Long-term Care Facilities
Antimicrobial resistance (AMR) is recognized as one of the major threats to global health [1], causing up to 25.000 deaths in the European Union every year, longer hospitalizations and increased healthcare costs.
- Trial name
- PreMDRinLTCF (NCT07234734)
- Where
- Italy
- Volunteers
- 581 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
NAsal MEthicillin-resistant Staphylococcus
NAsal MEthicillin-resistant Staphylococcus (NAMES): a Prospective Study to Assess the Impact of Antibiotic Therapy on Nasal Colonization with Methicillin-resistant Staphylococcus Aureus (MRSA) Inhospitalized Children
Antimicrobial resistance (AMR) is recognized as one of the major threats to global health [1], causing up to 25.000 deaths in the European Union every year, longer hospitalizations and increased healthcare costs.
- Trial name
- NAMES (NCT06872099)
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia